Literature DB >> 4999930

Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?

A Marble.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4999930     DOI： 10.2165/00003495-197101020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  9 in total

1.  [A new anti-diabetes principle; results of clinical research].

Authors:  H FRANKE; J FUCHS
Journal:  Dtsch Med Wochenschr       Date:  1955-10-07       Impact factor: 0.628

2.  Pathological findings after long-term sulfonylurea therapy.

Authors:  M C Balodimos; A Marble; J H Rippey; M A Legg; T Kuwabara; R E Gleason
Journal:  Diabetes       Date:  1968-08       Impact factor: 9.461

3.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

Authors:  C L Meinert; G L Knatterud; T E Prout; C R Klimt
Journal:  Diabetes       Date:  1970       Impact factor: 9.461

4.  Preliminary clinical evaluation of glybenclamide in treatment of diabetes mellitus.

Authors:  B F Johnson; C K Bhatia; W J Rzeszotarski; F W Wolff
Journal:  Diabetes       Date:  1970-08       Impact factor: 9.461

Review 5.  The Banting Memorial Lecture 1967. Angiopathy in diabetes: an unsolved problem.

Authors:  A Marble
Journal:  Diabetes       Date:  1967-12       Impact factor: 9.461

6.  Diabetic angiopathy and sulfonylurea therapy.

Authors:  M C Balodimos; A Marble
Journal:  Minn Med       Date:  1968-10

7.  Are antidiabetic drugs dangerous?

Authors: 
Journal:  Br Med J       Date:  1970-11-21

8.  Long-term tolbutamide treatment after myocardial infarction. A clinical and biochemical study of 178 patients without overt diabetes.

Authors:  J Paasikivi
Journal:  Acta Med Scand Suppl       Date:  1970

9.  [A new highly-active oral antidiabetic].

Authors:  W Aumüller; A Bänder; R Heerdt; K Muth; W Pfaff; F H Schmidt; H Weber; R Weyer
Journal:  Arzneimittelforschung       Date:  1966-12
  9 in total
  9 in total

1.  Role of Glibenclamide in Brain Injury After Intracerebral Hemorrhage.

Authors:  Bing Jiang; Lin Li; Qianwei Chen; Yihao Tao; Liming Yang; Bo Zhang; John H Zhang; Hua Feng; Zhi Chen; Jun Tang; Gang Zhu
Journal:  Transl Stroke Res       Date:  2016-11-03       Impact factor: 6.829

2.  Changes in the vascular beta-adrenoceptor-activated signalling pathway in 2Kidney-1Clip hypertensive rats.

Authors:  Glaucia E Callera; Ester Yeh; Rita C A Tostes; Luciana C Caperuto; Carla R O Carvalho; Lusiane M Bendhack
Journal:  Br J Pharmacol       Date:  2004-03-08       Impact factor: 8.739

Review 3.  BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema.

Authors:  Melissa Pergakis; Neeraj Badjatia; Seemant Chaturvedi; Carolyn A Cronin; W Taylor Kimberly; Kevin N Sheth; J Marc Simard
Journal:  Expert Opin Investig Drugs       Date:  2019-10-24       Impact factor: 6.206

Review 4.  Glibenclamide for the treatment of ischemic and hemorrhagic stroke.

Authors:  Nicholas Caffes; David B Kurland; Volodymyr Gerzanich; J Marc Simard
Journal:  Int J Mol Sci       Date:  2015-03-04       Impact factor: 5.923

Review 5.  A Protective Role of Glibenclamide in Inflammation-Associated Injury.

Authors:  Gensheng Zhang; Xiuhui Lin; Shufang Zhang; Huiqing Xiu; Chuli Pan; Wei Cui
Journal:  Mediators Inflamm       Date:  2017-06-27       Impact factor: 4.711

6.  Effectiveness and safety of glibenclamide for stroke: protocol for a systematic review and meta-analysis.

Authors:  Lihong Wen; Bin Huang; Rong Tu; Kunzhen Wan; Hong Zhang; Xiaoyun Zhang
Journal:  BMJ Open       Date:  2021-05-10       Impact factor: 2.692

Review 7.  Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

Authors:  Surojit Paul; Eduardo Candelario-Jalil
Journal:  Exp Neurol       Date:  2020-11-02       Impact factor: 5.330

8.  Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer.

Authors:  Zhe Rong; Li Li; Fei Fei; Lailong Luo; Yang Qu
Journal:  J Exp Clin Cancer Res       Date:  2013-05-28

9.  Glibenclamide for the treatment of acute CNS injury.

Authors:  David B Kurland; Cigdem Tosun; Adam Pampori; Jason K Karimy; Nicholas M Caffes; Volodymyr Gerzanich; J Marc Simard
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.